How do I estimate the true cost of a failed cell therapy batch?

Use Cell Therapy Batch Failure Cost, which sums the consumed single-use kit, media, cleanroom occupancy hours, operator labor, and released QC testing for a batch that fails before disposition. For autologous products, add the schedule impact of re-collecting apheresis material. A failed lot frequently carries 40 to 60 percent of a successful batch's cost with zero salable output, which is why suites protect yield aggressively.

How many doses can one bioreactor produce per run?

Run Cell Therapy Bioreactor Capacity with your working volume and target cell density, then apply Cell Expansion Yield to convert seeded cells into viable dose-ready cells after your expected fold expansion and post-harvest losses. A run that expands 20-fold but loses 15 percent at fill-finish yields far fewer doses than the raw expansion suggests, so the two calculators are always run as a pair.

What GMP cleanroom utilization should a cell therapy suite target?

Most Grade B and C suites plan for 50 to 70 percent occupancy on scheduled hours because gowning, cleaning, and changeover between batches consume real time. GMP Cleanroom Utilization Cost converts suite hours plus HVAC, gowning, and environmental monitoring into a per-batch occupancy cost. Pair it with Process Hold Time so you see how much suite time is standby versus productive.

How do I quantify the documentation and deviation burden of a new process?

GMP Documentation Burden Score weighs batch record steps, in-process checks, and sign-offs to estimate the review effort per lot, while GMP Deviation Cost prices the investigation, CAPA, and QA hours a typical deviation triggers. Together they show why a process with 300 record entries and a 5 percent deviation rate can add days to lot release, which feeds directly into Compliance Review Equipment Load.

How much cryostorage capacity do I need for a scaled program?

Cryostorage Capacity converts your annual dose forecast, retention samples, and stability pulls into required LN2 dewar or controlled-rate freezer positions, including headspace for peak inventory. Because doses may sit frozen for months awaiting patient scheduling, plan for 2 to 3 times the monthly output in positions. Undersizing here strands finished product and blocks new batches from releasing into storage.

How do I price a CDMO cell therapy manufacturing slot with margin?

Cell Therapy Quote Margin builds up media, single-use kits, cleanroom occupancy, QC testing, and documentation cost per batch, then applies your batch failure probability as a risk loading before margin. A 10 percent failure rate effectively raises your cost base by roughly 11 percent on surviving batches, so quoting on nominal cost alone erodes margin. Feed in Cell Therapy Batch Failure Cost and Validation Batch Cost for a defensible price.

Manufacturing calculator category

Cell Therapy & Gene Therapy Equipment calculators

This hub covers the capacity, cost, and quality math behind cell and gene therapy manufacturing, from bioreactor sizing and expansion yield to cleanroom utilization and batch failure exposure. It is built for process development scientists, MSAT engineers, and manufacturing planners at CDMOs and therapy developers who need defensible numbers before locking a production plan.

What this hub covers

Free calculators for autologous and allogeneic cell and gene therapy production: bioreactor capacity, expansion yield, cleanroom cost, batch failure risk, and GMP burden.
Browse cell therapy & gene therapy equipment calculators for manufacturing planning, quoting, quality, capacity, and operations decisions.

Best calculators in this category

Cell Therapy Bioreactor Capacity: Estimate monthly viable culture capacity from available bioreactor runs, planned uptime, and release yield.
Cell Expansion Yield: Calculate harvested viable cell yield against the target cell count for a patient batch, donor lot, or expansion run.
GMP Cleanroom Utilization Cost: Estimate the cost of occupied GMP cleanroom suite hours for cell therapy or gene therapy production.
Cell Therapy Batch Failure Cost: Estimate expected financial exposure from failed, contaminated, or unreleased cell therapy and gene therapy batches.
Single-Use Kit Cost: Estimate disposable tubing set, bag, cartridge, filter, and closed-processing kit cost for a batch or campaign.
Sterility Test Equipment Load: Estimate energy cost and sample-normalized load for sterility test incubators, readers, and supporting QC equipment.
Cryostorage Capacity: Estimate usable cryogenic storage capacity for cryobags, vials, cassettes, or patient-specific inventory.
Chain-of-Identity Equipment Workload: Estimate operating cost for chain-of-identity scanners, labelers, workstations, and verification equipment during production.
Validation Batch Cost: Estimate the cost of PPQ, engineering, media-fill, or process validation batches for cell and gene therapy equipment.
GMP Documentation Burden Score: Score the burden created by batch records, equipment logs, chain-of-custody records, and GMP review requirements.
GMP Deviation Cost: Estimate expected cost from deviations, investigations, CAPAs, and repeat work in cell and gene therapy manufacturing.
Operator Support Equipment Load: Estimate the energy cost of operator-facing equipment used during cell therapy and gene therapy production shifts.

Common manufacturing problems solved

cell
therapy
gene
manufacturing

Live market signals for this industry

U.S. manufacturing runs at 75.6% of capacity with new factory orders at $657B per month (Federal Reserve and Census, Jun 2026).
Steel mill PPI stands at 361.439 (BLS, Jun 2026), up 16.9% from a year earlier. New factory orders are up 7.4% year over year (Census).

Category questions

How do I estimate the true cost of a failed cell therapy batch? Use Cell Therapy Batch Failure Cost, which sums the consumed single-use kit, media, cleanroom occupancy hours, operator labor, and released QC testing for a batch that fails before disposition. For autologous products, add the schedule impact of re-collecting apheresis material. A failed lot frequently carries 40 to 60 percent of a successful batch's cost with zero salable output, which is why suites protect yield aggressively.
How many doses can one bioreactor produce per run? Run Cell Therapy Bioreactor Capacity with your working volume and target cell density, then apply Cell Expansion Yield to convert seeded cells into viable dose-ready cells after your expected fold expansion and post-harvest losses. A run that expands 20-fold but loses 15 percent at fill-finish yields far fewer doses than the raw expansion suggests, so the two calculators are always run as a pair.
What GMP cleanroom utilization should a cell therapy suite target? Most Grade B and C suites plan for 50 to 70 percent occupancy on scheduled hours because gowning, cleaning, and changeover between batches consume real time. GMP Cleanroom Utilization Cost converts suite hours plus HVAC, gowning, and environmental monitoring into a per-batch occupancy cost. Pair it with Process Hold Time so you see how much suite time is standby versus productive.
How do I quantify the documentation and deviation burden of a new process? GMP Documentation Burden Score weighs batch record steps, in-process checks, and sign-offs to estimate the review effort per lot, while GMP Deviation Cost prices the investigation, CAPA, and QA hours a typical deviation triggers. Together they show why a process with 300 record entries and a 5 percent deviation rate can add days to lot release, which feeds directly into Compliance Review Equipment Load.
How much cryostorage capacity do I need for a scaled program? Cryostorage Capacity converts your annual dose forecast, retention samples, and stability pulls into required LN2 dewar or controlled-rate freezer positions, including headspace for peak inventory. Because doses may sit frozen for months awaiting patient scheduling, plan for 2 to 3 times the monthly output in positions. Undersizing here strands finished product and blocks new batches from releasing into storage.

Last reviewed 2026-05-12.